Skip to main content

01.12.2015 | Research article | Ausgabe 1/2015 Open Access

BMC Palliative Care 1/2015

The application of the palliative prognostic index, charlson comorbidity index, and Glasgow prognostic score in predicting the life expectancy of patients with hematologic malignancies under palliative care

BMC Palliative Care > Ausgabe 1/2015
Wen-Chi Chou, Chen-Yi Kao, Po-Nan Wang, Hung Chang, Hung-Ming Wang, Pei-Hung Chang, Kun-Yun Yeh, Yu-Shin Hung
Wichtige Hinweise

Competing interests

This research was not funded by any public, commercial, or nonprofit agency. No competing financial interests exist.

Authors’ contributions

WCC and CYK participated in the study design. YSH conceived of the study and drafted the manuscript. PNW, HC and HMW edited subsequent versions of manuscript. WCC, PHC and KYY carried out the data analysis. All authors read and approved the final manuscript.



The clinical course for hematologic malignancy varies widely and no prognostic tool is available for patients with a hematologic malignancy under palliative care. To assess the application of the Palliative Prognostic Index (PPI), Charlson Comorbidity Index (CCI), and Glasgow Prognostic Score (GPS) as prognostic tools in patients with hematologic malignancies under palliative care.


We included 217 patients with pathologically proven hematologic malignancies under palliative care consultation service (PCCS) between January 2006 and December 2012 at a single medical center in Taiwan. Patients were categorized into subgroups by PPI, CCI, and GPS for survival analysis.


The median survival was 16 days (interquartile range, 4–47.5 days) for all patients and 204 patients (94%) died within 180 days after PCCS. There was a significant difference in survival among patients categorized using the PPI (median survival 49, 15, and 7 days in patients categorized into a good, intermittent, and poor prognostic group, respectively) and the GPS (median survival 66 and 13 days for GPS 0 and 1, respectively). There was no difference in survival between patients with a GPS score of 0 versus 2, or a CCI score of 0 versus ≥1. The survival time was significantly discriminated after stratifying patients with a good PPI score based on the CCI (median survival 102 and 41 days in patients with a CCI score of 0 and ≥1, respectively) from those with a poor PPI score by using the GPS (median survival 47 and 7 days in patients with GPS scores of 0 and 1–2, respectively).


PPI is a useful prognosticator of life expectancy in terminally ill patients under palliative care for a hematologic malignancy. Concurrent use of the GPS and CCI improved the accuracy of prognostication using the PPI.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Palliative Care 1/2015 Zur Ausgabe

Neu im Fachgebiet AINS

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update AINS und bleiben Sie gut informiert – ganz bequem per eMail.